Cardioband Feasible, Demonstrating 30-Day Improvements in TR, Quality of Life and Functional Status
In the first U.S. Food and Drug Administration (FDA) approved early feasibility study (EFS) of the Cardioband tricuspid system, 30 patients with severe tricuspid regurgitation (TR) underwent successful direct transcatheter annular reduction with 93% procedural success, 100% survival and significant reductions in TR which translated to improvements in quality of life and functional status at 30 days, according to results released Monday.